Zepbound Assistance Programs & Grants in Utah

Status: Active for commercially insured patients; "Card expires and savings end on 12/31/2026." Not valid for single-dose vials.

A commercial copay offer: as little as $25 per fill for commercially insured patients whose plan covers the single-dose pen (maximum $1,300 savings a year), or $499 a month for the pen and $299–$449 for the KwikPen when a commercial plan does not cover Zepbound.

If you have Medicare: Lilly's terms require that "You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, or any state prescription drug assistance program." Anyone who later gains government coverage must stop using the card.

Status: Self-pay prices on August 26, 2026: $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5–15 mg when you refill within 45 days (otherwise $499 for 7.5 mg and $699 for 10–15 mg). The same prices apply to single-dose vials (LillyDirect only) and the KwikPen (LillyDirect, or any retail pharmacy with the Self-Pay Savings Card). The single-dose pen has no self-pay price.

Lilly's direct-to-patient channel, plus a retail cash card for the KwikPen launched March 16, 2026 that Lilly says "is available to all patients, including those without insurance coverage." For a Part D enrollee who does not qualify for the Bridge — for example because Zepbound is prescribed for sleep apnea and the plan will not cover it — this is the price to compare. Cash purchases do not count toward the $2,100 Part D cap.

If you have Medicare: The self-pay terms contain no Medicare or government-program exclusion — unlike the commercial card — and Lilly's savings page shows the self-pay option under its "Medicare" selection. But no sentence says outright that Medicare enrollees may buy. What the terms do require: you "will not seek or accept reimbursement … from any third-party payer, including private insurance or state or federal healthcare programs, nor apply those costs toward any deductible or true out-of-pocket requirements." Treat it as a cash purchase outside your plan and confirm with LillyDirect Customer Care first.

What it can cover: A cash price of $299–$449 a month (regular price $299–$699) for the Zepbound KwikPen or single-dose vials; the federal TrumpRx site lists the same $299 starting price and routes orders to LillyDirect.

Status: Closed to new applicants on August 26, 2026. Zepbound and Zepbound KwikPen (tirzepatide) are on the fund's approved-medication list. Zepbound is also listed under the closed Type 2 diabetes, Type 2 diabetes health equity and Stroke funds and the OPEN MASH fund — none of which matches a weight-management or sleep-apnea prescription. There is no sleep-apnea fund.

Patient Advocate Foundation's TotalAssist (launched July 1, 2026, combining PAF Co-Pay Relief and the PAN Foundation) lists Zepbound under its Obesity fund. A listing is not an open fund. Sign up to be notified the moment it reopens — there is no waitlist or queue.

If you have Medicare: Unusually, the Obesity fund accepts any health insurance, not only government coverage — but it requires insurance "that covers your qualifying expenses." Part D does not cover Zepbound for weight loss, and whether a grant can reimburse the Bridge's $50 copay, which sits outside Part D, is not addressed anywhere on totalassist.org. Ask TotalAssist directly before counting on it.

What it can cover: When open: $1,000 guaranteed award, $2,000 maximum, for eligible out-of-pocket costs; household income at or below 300% of the federal poverty level, adjusted for regional cost of living.

Status: Live since July 1, 2026 and extended through December 31, 2027 (checked August 26, 2026). Covers the Zepbound KwikPen only — CMS: "The single-dose Zepbound pen and Zepbound vials are NOT covered." Pen needles are not covered either.

A CMS demonstration that stands in for Part D coverage of weight-management GLP-1s until the end of 2027. Your cost is $50 for a one-month supply "no matter your income level"; the Part D deductible does not apply, and the payment does not count toward your deductible, out-of-pocket limit or Medicare Prescription Payment Plan. Approval, once granted, lasts through December 31, 2027 including refills and dose changes, as long as you stay on the same drug. CMS notes there is no appeals process under the Bridge.

If you have Medicare: For Medicare Part D enrollees (stand-alone plans, Medicare Advantage drug plans, Special Needs Plans and employer group plans; not PFFS, cost, PACE or fallback plans). Medicare.gov: "You aren't eligible if you: Already get GLP-1 drugs covered through your Medicare Part D plan. Have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (but your Part D plan might cover your GLP-1s)." Dual-eligible beneficiaries in an eligible plan can use it. CMS: "no part of the $50 copay counts towards the beneficiary's TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries."

What it can cover: The Zepbound KwikPen (all six strengths) at a flat $50 per one-month supply. Not the single-dose pen, not vials, not pen needles.